No statistically significant associations were found between KRAS or BRAF mutations and age, tumor size, laterality, cytology, FIGO stage, ascites, ovarian surface involvement, cancer antigen 125 concentration, metastases or lymph node involvement (all, P > 0.05) (Table 1). Here, MUC16 is linked to neoplasm.